Advanced Search

Home > Journals > Minerva Urologica e Nefrologica > Archive > Minerva Urologica e Nefrologica 2013 March;65(1) > Minerva Urologica e Nefrologica 2013 March;65(1):37-50

CURRENT ISSUE   ARCHIVE   EPUB AHEAD OF PRINT   MOST READ   eTOC


MINERVA UROLOGICA E NEFROLOGICA

Minerva Urologica e Nefrologica 2013 March;65(1):37-50

MANAGEMENT IN KIDNEY DISEASES 

Hypertension and chronic kidney disease: controversies in pathogenesis and treatment

Pirkle J. L., Freedman B. I.

Section on Nephrology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA

The relationship between hypertension and chronic kidney disease (CKD) has long been the subject of controversy. The pathogenetic mechanisms of nephropathy in non-diabetic individuals with hypertension, as well as optimal hypertension treatment targets in populations with nephropathy remain important clinical concerns. This manuscript reviews breakthroughs in molecular genetics that have clarified the complex relationship between hypertension and kidney disease, answering the question of which factor comes first. An overview of the potential roles that hyperuricemia plays in the pathogenesis of hypertension and CKD and current blood pressure treatment guidelines in populations with CKD are discussed. The ongoing National Institutes of Health-sponsored Systolic Blood Pressure Intervention Trial (SPRINT) is underway to help answer these important questions. Enrollment of 9250 hypertensive SPRINT participants will be completed in 2013; important results on ideal blood pressure control targets for reducing nephropathy progression, cardiovascular disease end-points, and preserving cognitive function are expected. As such, many of the controversial aspects of hypertension management will likely be clarified in the near future.

language: English


FULL TEXT  REPRINTS

top of page